Form 8-K - Current report:
SEC Accession No. 0001193125-24-285960
Filing Date
2024-12-27
Accepted
2024-12-27 16:37:01
Documents
15
Period of Report
2024-12-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d924954d8k.htm   iXBRL 8-K 27735
2 EX-4.1 d924954dex41.htm EX-4.1 12665
  Complete submission text file 0001193125-24-285960.txt   202586

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dvax-20241226.xsd EX-101.SCH 3878
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dvax-20241226_def.xml EX-101.DEF 13674
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20241226_lab.xml EX-101.LAB 22623
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20241226_pre.xml EX-101.PRE 14642
18 EXTRACTED XBRL INSTANCE DOCUMENT d924954d8k_htm.xml XML 5486
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 241586082
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)